FDMT - Company ID 0001650648
The table below shows 4D Molecular Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $60.24M | $149.34M | $249.11M | $52.35M | $153.00M | $276.73M |
| Short-term investments | $342.41M | $275.54M | $39.12M | $161.20M | $94.78M | - |
| Receivables | - | - | - | $0.00 | $47.00K | $1.49M |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $413.13M |
| $434.93M |
| $296.59M |
| $220.51M |
| $256.28M |
| $282.66M |
| Property, plant & equipment | $14.87M | $19.53M | $20.13M | $22.26M | $14.39M | $5.07M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $566.71M | $560.38M | $339.89M | $261.85M | $353.49M | $288.33M |
| Accounts payable | $11.16M | $4.39M | $3.52M | $3.32M | $4.76M | $1.79M |
| Total current liabilities | $43.98M | $29.15M | $18.95M | $15.73M | $16.34M | $16.74M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $61.05M | $49.78M | $32.06M | $30.51M | $34.38M | $31.94M |
| Retained earnings | -$716.30M | -$576.20M | -$415.33M | -$314.49M | -$207.00M | -$135.68M |
| Total equity | $505.66M | $510.61M | $307.83M | $231.34M | $319.11M | $256.39M |